NasdaqGM:EYPTPharmaceuticals
A Look At EyePoint (EYPT) Valuation As DURAVYU Phase 3 Safety Review Keeps Trials On Track
The latest review by the independent Data Safety Monitoring Committee of EyePoint (EYPT) pivotal Phase 3 DURAVYU program kept both LUGANO and LUCIA trials on course, with interim masked data indicating a continued favorable safety profile.
See our latest analysis for EyePoint.
EyePoint’s recent safety update for DURAVYU comes after a sharp share price pullback this year, with the stock down 26.03% on a year to date share price return but still showing a 127.64% total shareholder return over...